Sanochemia Pharmazeutika AG, announces positive topline results from the "STAR Study", a Phase 2 dose-ranging study tolperisone in acute muscle spasms of the back, conducted by its partner Neurana Pharmaceuticals Inc. in the U.S. The STAR Study is a double-blind, randomized, placebo-controlled, parallel-group Phase 2 study designed to evaluate the efficacy and safety of tolperisone in various daily doses or placebo administered three times a day (TID) in male and female study participants experiencing acute back pain due to or associated with muscle spasm. The study consisted of 415 patients and was conducted at 38 sites throughout the United States. The primary objective of the study was to assess the efficacy of various daily doses of tolperisone to determine the dose to be used for the planned Phase 3 clinical program. Overall, the STAR Study demonstrated the efficacy of tolperisone with a p value of 0,004 for the 600 mg dose and a very high tolerability of the drug confirming its lack of sedation.